Erdheim-Chester disease

Also found in: Acronyms, Wikipedia.

Erd·heim-Chester disease

rare systemic disorder characterized by proliferation of histocytes, by symmetric sclerosis at diametaphysial portions of lower limbs, and by extraskeletal involvement. Microscopically, infiltration of affected organs by lipophages and Touton giant cells is evident.
Farlex Partner Medical Dictionary © Farlex 2012
Mentioned in ?
References in periodicals archive ?
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
Erdheim-Chester disease has numerous signs and symptoms.
- The US Food and Drug Administration has approved Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation.
Swiss healthcare company Hoffman-LaRoche Inc reported on Monday the receipt of expanded approval from the US Food and Drug Administration for Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD) of the blood.
Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases.
Parisi, "Neurological manifestations of Erdheim-Chester disease," Journal of Neurology, Neurosurgery, and Psychiatry, vol.
Caparros-Lefebvre et al., "Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases," Medicine, vol.
Erdheim-Chester disease of the breast: a case report and review of the literature.
Annes et al., "Erdheim-Chester disease presenting with cutaneous involvement: a case report and literature review," Journal of Cutaneous Pathology, vol.
Erdheim-Chester disease is a systemic histiocytic disorder diagnosed on the basis of a characteristic pattern of symmetric intramedullary sclerosis of long bones.
And how do people living with rare illnesses such as Erdheim-Chester disease cope when treatment, research and services are limited?